Sandbox/table: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
|} | |} | ||
==table== | |||
{| style="border: 2px solid #DCDCDC; font-size: 90%; width: | {| style="border: 2px solid #DCDCDC; font-size: 90%; width: 50%;" | ||
|+ '''Laboratory findings''' | |+ '''Laboratory findings''' | ||
|- | |- | ||
Revision as of 18:59, 20 June 2014
The following table contains the main risk factors for CDI:[1][2][3][2][2]
| Alterations in the coagulation system |
|---|
| Consumption of clotting factors |
| Increased concentrations of fibrin degradation products |
| Disseminated intravascular coagulation |
table
| Test | Findings |
|---|---|
| White blood cells count | Leucopenia (1000 cells/μL), with lymphopenia and neutrophilia |
| Blood smear | Left shift with atypical lymphocytes |
| Liver function tests | Raised aspartate aminotransferase and alanine aminotransferase, extended prothrombin time and partial thromboplastin time. |
| Proteins | Hyperproteinemia. |
| Urinalysis | Proteinuria. |
table
| Diagnostic test | North America | South America | Middle East | Far East |
|---|---|---|---|---|
ELISA (serology) detects:
|
† There is a reported prevalence of 15% in the Northeast of the US.
- ↑ Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ (2012). "Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics". J Antimicrob Chemother. 67 (3): 742–8. doi:10.1093/jac/dkr508. PMID 22146873.
- ↑ 2.0 2.1 2.2 Knight, Christopher L.; Surawicz, Christina M. (2013). "Clostridium difficile Infection". Medical Clinics of North America. 97 (4): 523–536. doi:10.1016/j.mcna.2013.02.003. ISSN 0025-7125.
- ↑ Planche, Tim (2013). "Clostridium difficile". Medicine. 41 (11): 654–657. doi:10.1016/j.mpmed.2013.08.003. ISSN 1357-3039.